1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Hepatitis C: Game changing regimens to revolutionise treatment landscape - Consensus Outlook




The worldwide hepatitis C (HCV) market is forecast to grow from $4.7 billion in 2012 to $17.7 billion in 2017. The catalysts for this growth include a boost in diagnosis rates following an increase in screening, and the introduction more effective and tolerable pipeline agents.

Therapy Trends Consensus Outlook: Hepatitis C provides an in-depth analysis of the products players and events that will shape the future HCV market.

Therapy Trends Consensus Outlook: HIV includes the following comprehensive resources:




An in-depth forecast report based on consensus figures from 13 leading analysts. Rich in tables and charts, the report maps the impact of future events to predict product and company performance
An interactive forecast data analysis spreadsheet comparing critical market parameters including market size, product sales, market shares and competitive status over the period 2007 to 2017
Updated reports and data analysis files delivered to your inbox after each significant market event.







Key Benefits

Therapy Trends Consensus Outlook: Hepatitis C provides:

Evaluate future sales forecasts and predicted market growth
Map your market parameters and chart commercial prospects
Assess market share by company and product
Tailor your strategic and investment focus based on the competition
Set proactive launch and branding strategies
Keep up with event-driven market data updates




Forecast analysis report and data model

The forecast analysis report component of Consensus Outlook: Hepatitis C delivers a rich analysis of product-level sales forecast data and of the future events that underpin the forecasts. The product of meticulous FirstWord research, its historical sales data (2007–12) is based on company information, and the five-year (2013-17) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.

The report combines independent, unbiased, accurate forecasts with invaluable insights into factors that impact future product performance, backed-up by research of analysts who have an unrivalled level of intimacy with the market, the players, their products and their strategies.


Historical HCV sales from 2007–2012
Forecast HCV sales from 2013-2017
Key competitors and drug developers
Predicted product positioning
Current and late-stage pipeline drugs
Future event mapping to forecast data points
Comparative clinical trial results


FirstWord’s HCV forecast data model allows to you examine detailed Excel spreadsheets to quickly compare various market parameters.


Market size
Product sales
Company forecasts
Company, brand, and drug class
Mechanism of action Future events


Event Assessments

Stay a step ahead with Therapy Trends Consensus Outlook updates. Over the next 12 months, you will receive updated market analysis and forecast reports each time a major market event breaks. Updates will be delivered straight into your inbox within days of each event’s occurrence.

Whether it’s a predicted product approval or an unexpected late stage failure, Therapy Trends has the resources and knowledge to keep you up to date with the latest market analysis.




Methodology

For each Therapy Trends report, FirstWord analysts produce a data analysis module'a Consensus Outlook'which provides annual historical and forecast product-level sales data. Historical sales data is derived from company information, while the five-year (2012-2017) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.

Once a Therapy Trends data module is published, FirstWord analysts subsequently collate and evaluate the latest relevant reports published by equity research analysts and feed relevant updated forecasts into the Therapy Trends forecast model.

Consensus forecasts derived from the leading equity research analysts reflect the most up-to-date assessment of the pharmaceutical market, with equity analyst models updated to reflect a broad spectrum of events and catalysts, which range from the publication of quarterly financial results to in-depth discussions with leading key opinion leaders (KOLs). Consensus forecasts also act as an excellent benchmark against which other projections–produced either internally or by other third parties–can be assessed.

Equity research teams utilize a selection of analytical frameworks to generate product level forecasts, focusing heavily on patient and event based modelling. In addition to consensus forecasting, FirstWord Therapy Trend data modules also collate and analyse the key future events that are anticipated to impact product level forecasts and shape the broader context of a specific disease area – to produce a ‘consensus calendar’ of events designed to help inform FirstWord clients on how the market will evolve.

Leading equity research analysts have a deep intimacy with the prescription pharmaceutical market and the companies they cover; supported by unrivalled research resources, this highly analytical insight extends to the product franchises of these companies (driven by a ‘bottom-up’ forecasting methodology) and the strategic protocols being pursued by company management.





Table Of Contents

Hepatitis C: Game changing regimens to revolutionise treatment landscape - Consensus Outlook
1.Hepatitis C Marketplace
2.Key Hepatitis C Developers
3.Hepatitis C Class Dynamics
4. (sofosbuvir (GS-7977, Gilead) forecast
5.Olysio (simeprevir; Medivir/Tibotec) forecast
6.Incivek (telaprevir; Vertex Tibotec/Mitsubishi Tanabe) forecast
7.Victrelis (boceprevir; Merck) forecast
8.PegaSys (pegylated interferon-alpha; Roche) forecast
9.PegIntron (pegylated interferon-alpha; Merck) forecast
10.Abbott franchise (ABT-333/ABT-450/ABT-267; Abbott) forecast
11.Bristol-Myers Squibb franchise (daclastasvir/asunaprevir) forecast
12.Sovaprevir (ACH-1625; Achillion Pharmaceuticals) forecast
13.MK-5172 (Merck) forecast
14.Vaniprevir (MK-7009; Merck) forecast
15.VX-222 (Vertex) forecast


View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations Summary Hepatitis C is a blood-borne viral infection ...

2016-2021 Global Hepatitis Markers Testing Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices--Supplier Shares and Country Sales Segment Forecasts for 10 Immunodiagnostic and NAT Procedures

2016-2021 Global Hepatitis Markers Testing Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices--Supplier Shares and Country Sales Segment Forecasts for 10 Immunodiagnostic and NAT Procedures

  • $ 6250
  • Industry report
  • November 2016
  • by Venture Planning Group

The report presents a detailed analysis of the Hepatitis diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Hepatitis definition, epidemiology ...

2017-2021 Hepatitis Diagnostic Testing Market

2017-2021 Hepatitis Diagnostic Testing Market

  • $ 6250
  • Industry report
  • February 2017
  • by Venture Planning Group

The report presents a detailed analysis of the Hepatitis diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Hepatitis definition, epidemiology ...


Download Unlimited Documents from Trusted Public Sources

Type 2 Diabetes Statistics in the US

  • February 2017
    13 pages
  • Type 2 Diabetes  

    Diabetes  

  • United States  

View report >

Influenza Statistics in India

  • February 2017
    2 pages
  • Influenza  

    Infectious Dise...  

  • India  

    Asia  

View report >

Infectious Disease Statistics in the US

  • February 2017
    16 pages
  • Infectious Dise...  

  • United States  

    Nigeria  

View report >

Influenza Statistics

10 days ago

Related Market Segments :

Hepatitis

ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.